The impact of cost-effectiveness of country specific application-the case of drotrecogin alfa (activated) in severe sepsis

被引：0
|
作者：
Persson, U
Hjelmgren, J
Ragnarson, TG
Davies, A
机构：
[1] IHE, Lund, Sweden
[2] Medtap Int, London, England
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)61917-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：752 / 753
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of drotrecogin alfa (activated) (Xigris™) in severe sepsis
    Angus, DC
    Linde-Zwirble, WT
    Clermont, G
    Ball, DE
    Basson, BR
    Ely, EW
    Laterre, PF
    Vincent, JL
    Bernard, GR
    van Hout, B
    CRITICAL CARE MEDICINE, 2002, 30 (02) : 493 - 493
  • [2] Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis
    Angus, DC
    Linde-Zwirble, WT
    Clermont, G
    Ball, DE
    Basson, BR
    Ely, EW
    Laterre, PF
    Vincent, JL
    Bernard, G
    van Hout, B
    CRITICAL CARE MEDICINE, 2003, 31 (01) : 1 - 11
  • [3] Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany
    Neilson, AR
    Burchardi, H
    Chinn, C
    Clouth, J
    Schneider, H
    Angus, D
    JOURNAL OF CRITICAL CARE, 2003, 18 (04) : 217 - 227
  • [4] Cost-effectiveness of drotrecogin alfa (activated) in treating severe sepsis in the UK
    Davies, A
    Hutton, J
    Ridley, S
    Chinn, C
    Barber, B
    INTENSIVE CARE MEDICINE, 2002, 28 : S161 - S161
  • [5] Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany
    Neilson, AR
    Schneider, H
    Chinn, C
    Clouth, J
    Burchardi, H
    INTENSIVE CARE MEDICINE, 2002, 28 : S161 - S161
  • [6] Cost-effectiveness of drotrecogin alfa (activated) in treating severe sepsis in Sweden
    Hjelmgren, J
    Ragnarson, TG
    Persson, U
    Davis, A
    Finnern, HW
    Myren, KJ
    INTENSIVE CARE MEDICINE, 2003, 29 : S94 - S94
  • [7] Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis in Spain
    Sacristán, JA
    Prieto, L
    Huete, T
    Artigas, A
    Badia, X
    Chinn, C
    Hudson, P
    VALUE IN HEALTH, 2002, 5 (06) : 562 - 562
  • [8] Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom
    Green, C
    Dinnes, J
    Takeda, AL
    Cuthbertson, BH
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2006, 22 (01) : 90 - 100
  • [9] Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure
    França, LR
    Launois, R
    Le Lay, K
    Aegerter, P
    Bouhassira, M
    Meshaka, P
    Guidet, B
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2006, 22 (01) : 101 - 108
  • [10] Drotrecogin alfa (activated) in severe sepsis: A systematic review and new cost-effectiveness analysis
    Costa V.
    Brophy J.M.
    BMC Anesthesiology, 7 (1)
12345